In breast cancers, IL-6-expressing 4T1 mammary tumor-bearing mice were reported to dramatically enhance the recruitment of CD11b+Gr-1+ MDSCs in the spleen, primary tumor mass, and metastasizing organs when compared with low IL-6-expressing EMT6 mice (13). Here, IL6 is linked to breast carcinoma.